William Blair reduced their Q1 2026 EPS estimates for Bristol-Myers Squibb in a research report issued to clients and ...

William Blair reduced their Q1 2025 earnings per share (EPS) estimates for Sapiens International in a report released on Tuesday, February 18th. William Blair analyst D. Becker now anticipates that ...

The memo, and the surrounding uncertainty, caused investment bank William Blair to downgrade a wide number of companies, including Booz Allen, CACI, Leidos, and General Dynamics, to market perform ...

William Blair downgrades Booz Allen, CACI International, Leidos, Parsons and General Dynamics on the heightened risk of ...

William Blair downgraded Booz Allen (BAH) to Market Perform from Outperform.Discover the Best Stocks and Maximize Your Portfolio: See what ...

Repligen Corp (NASDAQ:RGEN) released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago ...

William Blair analyst Arjun Bhatia maintained a Buy rating on Radcom (RDCM – Research Report) today. The company’s shares opened today at ...

Founded by Josh Gerry who was most recently at LPL and with three decades of wealth industry experience, Chicago-based ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

West Pharmaceutical reported Q4 earnings and revenue above expectations but issued a weak 2025 forecast. William Blair ...

We recently compiled a list of the 10 AI News and Ratings Making Waves on Wall Street. In this article, we are going to take ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a ...